Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 9/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748504 | 0.86 | EGLN1 (0.44) | EGLN1HRH4DHODH | |
| SCHEMBL31748505 | 0.69 | CBFB (0.33) | EGLN1CBFB | |
| SCHEMBL31748611 | 0.69 | PSMB8 (0.41) | EGLN1DHODHCBFB | |
| SCHEMBL20479886 | 0.67 | PARP1 (0.46) | PARP1PARP2PKN1PKN2DHODH | |
| SCHEMBL30310686 | 0.67 | HRH4 (0.57) | EGLN1PARP1PARP2HRH4DHODH | |
| Carbamic Acid SCHEMBL7997388 | 0.67 | EGLN1 (0.49) | EGLN1PARP1HRH4DHODHCBFB | |
| SCHEMBL15939130 | 0.67 | HRH4 (0.57) | EGLN1PARP1PARP2HRH4DHODH | |
| SCHEMBL25679030 | 0.64 | DGAT1 (0.50) | PARP1DGAT1 | |
| SCHEMBL30707784 | 0.64 | HRH4 (0.44) | HRH4 | |
| SCHEMBL9107283 | 0.64 | HRH4 (0.44) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | EGLN1 3554/4885PARP1 902/4885PARP2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.